Fabien Zoulim

TL;DR: In this paper, the authors assess current understanding of hepatitis B virus (HBV), the disease that it causes, and its optimal management; and make recommendations for directions for future research, both basic and clinical Topics will include HBV replication and mode of inducing chronicity, the immunology of hepatitisB, the virus-host interactions, the natural history of chronic infection, and up-to-date results of trials of antiviral therapies, including peginterferon, lamivudine, adefovir dipivoxil, tenofovir, ent

TL;DR: This first evaluation showed that DNA chip technology can provide important information in relation to the clinical management of chronic hepatitis B by identifying an amino acid by the chip and determining the genotype of the virus in serum.

TL;DR: LVPs are a mixed population of particles, comprising predominantly subviral particles that represent a distinct class of modified lipoproteins within the TRL family.

TL;DR: It is reported that HBV cccDNA can be detected by Southern blot analyses in the liver of C57BL6 mice transduced with AAV-HBV, suggesting that the AAV -HBV/mouse model might be relevant to test drugs targeting HBVcccDNA regulation and persistence.

TL;DR: These guidelines for the use of the new protease inhibitors as part of a triple therapy, in combination with the standard therapy of peginterferon plus ribavirin, are proposed.